ArticleHemaSphere2026

Preclinical models of hepatosplenic γδ T-cell lymphoma with an activating STAT5B mutation display sensitivity to JAK inhibitor upadacitinib.

Myint Myat Khine Aung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.